NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Jul. 7, 2016--
Masimo (NASDAQ:
MASI) announced today that Deutsches Herzzentrum Berlin (DHZB / German
Heart Center Berlin) in Berlin, Germany, has adopted Masimo’s SedLine®
Brain Function Monitoring and O3™ Regional Oximetry technologies to
monitor patients in the operating room and intensive care unit.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160707005661/en/
“Our non-profit hospital performs over 32,000 treatments each year. Easy
access to advanced parameters and the data they provide are very
important for our patients, many of whom are undergoing especially
complex and critical operations,” stated Prof. Dr. Hermann Kuppe,
Director of the Department of Anesthesiology at DHZB, “Masimo’s
technology allows us to access multiple parameters quickly and
noninvasively from one monitor.”
SedLine brain function monitoring provides four channels of
electroencephalogram (EEG) to help clinicians better understand the
effects of anesthesia on the brain. SedLine monitors the effects of
anesthesia and sedation by monitoring electrical activity on both sides
of the brain. O3 regional oximetry provides regional oxygen saturation
(rSO2) and reference arterial oxygen saturation (SpO2)
information, helping clinicians detect regional hypoxemia that pulse
oximetry alone can miss.
“The innovative treatment programs at Deutsches Herzzentrum Berlin have
helped it to become recognized as one of the world’s leading centers for
cardiovascular medicine and transplantation. They have doctors, medical
students and scientific researchers from around the world apply to visit
the hospital as clinical observers every year,” stated Joe Kiani,
Founder and CEO of Masimo. “We are happy to see them adopt our SedLine
and O3 technologies and are impressed by their focus on patient safety.”
DHZB is a specialist hospital dedicated to the diagnosis and treatment
of cardiovascular and thoracic diseases, the implantation of mechanical
circulatory support systems, and heart and lung transplantations. A
cooperative partnership with Charité-Universitätsmedizin Berlin, each
year the hospital performs more than 6,700 operations, including 2,400
operations using heart-lung machines. DHZB treats more than 7,200
inpatients and 24,000 outpatients annually. The hospital has 194 beds,
71 of which are in intensive care. Since 2002, DHZB has received
certification by KTQ, the national quality control board, recognizing
the high standard of care DHZB provides. DHZB and its subsidiaries
employ 1,300 people, including 190 doctors and almost 500 nurses.
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated to be used
on more than 100 million patients in leading hospitals and other
healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive and
continuous monitoring of blood constituents that previously could only
be measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and
more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index
(PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect™ (MOC-9™)
interface. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7™ wearable patient monitor and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo’s SedLine® and O3™ technologies. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo’s SedLine® and O3™
technologies, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions with comparable accuracy
and unique advantages, including: immediate and continuous results that
enable earlier treatment without causing invasive trauma in all patients
and in every clinical situation; as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160707005661/en/
Source: Masimo
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com
or
Deutsches
Herzzentrum Berlin
Christian Maier, + 49 03 04 5931211
cmaier@dhzb.de